Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 05/23 10:00:46 pm
70.4 USD   -0.52%
05/23DJSamsung Targets U.S. Drug Market With Remicade Knockoff
05/23 BRISTOL MYERS S : to Hold Investor Teleconference to Discuss ASCO Hi..
05/20 INOVALON : Announces Agreement with Bristol-Myers Squibb to Focus on..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on BRISTOL-MYERS SQUIBB CO
05/23DJSamsung Targets U.S. Drug Market With Remicade Knockoff
05/23 BRISTOL MYERS SQUIBB : to Hold Investor Teleconference to Discuss ASCO Highlight..
05/20 INOVALON : Announces Agreement with Bristol-Myers Squibb to Focus on Real World ..
05/19 BRISTOL MYERS SQUIBB : and AbbVie Announce European Commission Approval of Empli..
05/19 BRISTOL MYERS SQUIBB : Trademark Application for "REAL-WORLD DATA ACROPOLIS" Fil..
05/19DJNew Hope for Melanoma Patients -- Update
05/18 BRISTOL MYERS SQUIBB : Two-Year Overall Survival Data from Two Pivotal Opdivo® (..
05/18DJNew Hope for Melanoma Patients
05/18 BRISTOL MYERS SQUIBB : FDA OKs immunotherapy drugs for bladder, blood cancers
05/18 BRISTOL MYERS SQUIBB : Breadth and Depth of Bristol-Myers Squibb’s Immuno-..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials